<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0002667'>Wilms tumor</z:hpo> gene WT1 is expressed at high levels in <z:e sem="disease" ids="C0376544" disease_type="Neoplastic Process" abbrv="">hematopoietic malignancies</z:e>, such as <z:hpo ids='HP_0001909'>leukemias</z:hpo> and <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>), and in various kinds of <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumors</z:e>, including <z:e sem="disease" ids="C0242379" disease_type="Neoplastic Process" abbrv="">lung cancer</z:e>, and it exerts an oncogenic function in these <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>IgM and IgG WT1 antibodies were measured by means of dot blot assay in 73 patients with <z:e sem="disease" ids="C0376544" disease_type="Neoplastic Process" abbrv="">hematopoietic malignancies</z:e> (16 <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> [<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>], 11 <z:hpo ids='HP_0006721'>acute lymphoid leukemia</z:hpo> [ALL], 13 <z:hpo ids='HP_0011010'>chronic</z:hpo> myeloid <z:hpo ids='HP_0001909'>leukemia</z:hpo> [<z:mp ids='MP_0005481'>CML</z:mp>], and 33 MDS) and 43 healthy volunteers </plain></SENT>
<SENT sid="2" pm="."><plain>Immunoglobulin IgM, IgG, and IgM+IgG WT1 antibodies were detected in 40 (54.8%), 40 (54.8%), and 24 (32.8%), respectively, of the 73 patients with <z:e sem="disease" ids="C0376544" disease_type="Neoplastic Process" abbrv="">hematopoietic malignancies</z:e>, whereas 7 (16.2%), 2 (4.7%), and none of the 43 healthy volunteers had IgM, IgG, or IgM+IgG WT1 antibodies, respectively </plain></SENT>
<SENT sid="3" pm="."><plain>Furthermore, immunoglobulin isotype class switching of WT1 antibodies from IgM to IgG occurred in conjunction with disease progression from <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> (RA) to RA with excess of blasts (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>), and further to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> in transformation (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>-t) in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients </plain></SENT>
<SENT sid="4" pm="."><plain>These results showed that humoral immune responses against the WT1 protein could be elicited in patients with WT1-expressing <z:e sem="disease" ids="C0376544" disease_type="Neoplastic Process" abbrv="">hematopoietic malignancies</z:e>, and they suggested that the helper T-cell responses needed to induce humoral immune responses and immunoglobulin isotype class switching from IgM to IgG were also generated in these patients </plain></SENT>
<SENT sid="5" pm="."><plain>Our findings may provide new insight into the rationale for elicitation of cytotoxic T-cell responses against the WT1 protein in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> immunotherapy using the WT1 vaccine </plain></SENT>
</text></document>